Mentions of artificial intelligence increased in the pharmaceutical industry in Q1 2023
Notably, artificial intelligence was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of batteries and environment, according to GlobalData.
Of the 50 leading companies in the pharmaceutical industry, Novartis had the greatest increase in references for artificial intelligence in Q1 2023, compared with the previous quarter. GlobalData identified 129 artificial intelligence-related sentences in the company’s filings – 59% of all sentences – and an increase of 6300% in Q1 2023 compared with Q4 2022. GSK’s mentions of artificial intelligence rose by 4400% to 45 and Moderna’s by 1400% to 15 and Johnson & Johnson’s by 100% to 9 and ICON’s by 300% to 4.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for artificial intelligence in Q1 2023 was 100.
To further understand GlobalData’s analysis on Artificial Intelligence (AI) in Drug Discovery Market – Thematic Research, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.
Source link
#Mentions #artificial #intelligence #increased #pharmaceutical #industry
